

CO-FOUNDER NEEDED

Technology for prophylactics and therapy

VACCINOLOGICS

THE PROBLEM

Platform technology with applications in cancer and infectious disease. We have preclinical (mouse) data in cancer (melanoma) and pneumonia (*Streptococcus pneumonia* infection).

OUR SOLUTION

A vaccine platform for prophylactic and therapeutic treatments.

PATENT STATUS

Yes, parts of the technology covered by patent in PCT.

FINANCIAL OVERVIEW

Soft funding from SPARK Denmark for cancer arm (ends December 2025).

Soft funding from EU for cancer arm (ends August 2028).

Soft funding from NNF Innovator for infectious disease arm (ends August 2028).

MILESTONES ACHIEVED

In vivo proof-of-principle.

TARGET MARKET & CUSTOMERS

Partnering with Pharma; Maturing and de-risking through investments.

CO-FOUNDER PROFILE WE ARE LOOKING FOR Must-have qualifications/background

 Fundraising and leading investor dialogues.
Desire to take lead of commercial development in collaboration with the team at DTU.

Nice-to-have qualifications/background

• Experience with vaccine development. Experience from Biotech/Pharma.

Personal fit

• Bring a commercial mindset, drive soft and hard fundraising.

TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

Get to know the potential and limitations of the technology.

Develop a plan for platform development with the team.

Prepare a slide deck for a Lundbeck Frontiers Grant.

Scout soft and philanthropic funding options.

Identify KOLs and clinical stakeholders for the different applications.

ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS

Mads H. Clausen, professor, PhD.


Has co-founded three spin-outs (GlycoSpot, ROS Therapeutics, Aptol Pharma).

Natalia Skinder, postdoc, PhD.

Is new to entrepreneurship.

PHYSICAL ADDRESS

DTU Chemistry Kemitorvet 207 2800 Kgs. Lyngby iNKT cell lipid agonist therapies



Tumor cell or APC

ABOUT OPEN ENTREPRENEURSHIP